Stock Track | Harrow Health Plunges 10.66% as Q3 Earnings and Revenue Miss Estimates

Stock Track11-11

Harrow Health Inc (HROW) saw its stock price plummet 10.66% on Monday following the release of its third-quarter 2025 financial results, which fell significantly short of analysts' expectations. The specialty pharmaceutical company's disappointing performance triggered a sell-off among investors in the after-hours trading session.

The company reported an adjusted earnings per share (EPS) of $(0.12), missing the estimated $0.26 by a wide margin. Revenue for the quarter came in at $71.638 million, also falling short of the anticipated $73.705 million. This double miss on both top and bottom lines appears to have spooked investors, leading to the sharp decline in share price.

Despite some positive metrics, such as a core gross margin of 81% and a core EPS of $0.33, the overall results were overshadowed by the missed estimates. Chief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. However, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market. The market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189985938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189985938","market":"us","top_or_hot":-1,"title":"Stock Track | Harrow Health Plunges 10.66% as Q3 Earnings and Revenue Miss Estimates","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) saw its stock price plummet 10.66% on Monday following the release of its third-quarter 2025 financial results, which fell significantly short of analysts' expectations. The specialty pharmaceutical company's disappointing performance triggered a sell-off among investors in the after-hours trading session.</p>\n\n<p>The company reported an adjusted earnings per share (EPS) of $(0.12), missing the estimated $0.26 by a wide margin. Revenue for the quarter came in at $71.638 million, also falling short of the anticipated $73.705 million. This double miss on both top and bottom lines appears to have spooked investors, leading to the sharp decline in share price.</p>\n\n<p>Despite some positive metrics, such as a core gross margin of 81% and a core EPS of $0.33, the overall results were overshadowed by the missed estimates. Chief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. However, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market. The market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Plunges 10.66% as Q3 Earnings and Revenue Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Plunges 10.66% as Q3 Earnings and Revenue Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) saw its stock price plummet 10.66% on Monday following the release of its third-quarter 2025 financial results, which fell significantly short of analysts' expectations. The specialty pharmaceutical company's disappointing performance triggered a sell-off among investors in the after-hours trading session.</p>\n\n<p>The company reported an adjusted earnings per share (EPS) of $(0.12), missing the estimated $0.26 by a wide margin. Revenue for the quarter came in at $71.638 million, also falling short of the anticipated $73.705 million. This double miss on both top and bottom lines appears to have spooked investors, leading to the sharp decline in share price.</p>\n\n<p>Despite some positive metrics, such as a core gross margin of 81% and a core EPS of $0.33, the overall results were overshadowed by the missed estimates. Chief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. However, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market. The market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1189985938","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189985938","pubTimestamp":1762822961,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc (HROW) saw its stock price plummet 10.66% on Monday following the release of its third-quarter 2025 financial results, which fell significantly short of analysts' expectations. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"个股追踪|哈罗健康跌10.66%Q3盈利营收不及预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) saw its stock price plummet 10.66% on Monday following the release of its third-quarter 2025 financial results, which fell significantly short of analysts' expectations. The specialty pharmaceutical company's disappointing performance triggered a sell-off among investors in the after-hours trading session.\nThe company reported an adjusted earnings per share (EPS) of $(0.12), missing the estimated $0.26 by a wide margin. Revenue for the quarter came in at $71.638 million, also falling short of the anticipated $73.705 million. This double miss on both top and bottom lines appears to have spooked investors, leading to the sharp decline in share price.\nDespite some positive metrics, such as a core gross margin of 81% and a core EPS of $0.33, the overall results were overshadowed by the missed estimates. Chief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. However, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market. The market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189985938","isCrawlerRequest":true}